Donostia

• Clinical trial of MK-7648A in adults and children with skin cancer Not authorised
  2022-501417-31-00 5 High-risk Resected Melanoma
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Not authorised
  2023-504231-41-00 10 Locally advanced or metastatic urothelial cancer
• Clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas Not authorised
  2024-514827-40-00 9 Patients with advanced soft-tissue sarcoma (leiomyosarcoma or malignan
• Utility of the use of N-acetylcisteine associated with conventional treatment in patients with severe acute alcoholic hepatitis (Maddrey>=32 … Pending
  2023-510163-35-00 5 Acute Alcoholic hepatitis
• Efficacy and safety of Ursodeoxycholic Acid as a new therapy for the treatment of hepatorenal polycystic diseases, genetic study and determi … Pending
  2024-513644-28-00 4 Hepatorenal polycystic diseases
• A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease Pending
  2024-515448-22-00 4 Parkinson
• A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP … Pending
  2024-516570-30-00 4 Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
• Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br … Pending
  2024-518026-32-00 5 Invasive Breast Cancer
• Ursodeoxycolic acid for the prevention of relapsing complications after gallstone acute pancreatitis, a double-blind multicenter randomized- … Pending
  2024-518237-28-00 6 recurrence of acute biliary pancreatitis
• Clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas Pending
  2024-520318-23-00 9 Patients with advanced soft-tissue sarcoma (leiomyosarcoma or malignan
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• Optimising TREATment for severe Gram-Negative Bacterial infections. Pending
  2025-521476-65-00 6 Severe Gram-Negative Bacterial infections
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Pending
  2025-521587-35-00 5 Metastatic colorectal cancer
• STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer Pending
  2025-522145-21-00 5 Metastatic hormone sensitive prostate cancer
• A trial to compare treatment with surlorian (ARM210, S48168) to placebo in effects on muscle strength and safety in adults with autosomal do … Pending
  2025-522343-18-00 4 Autosomal Dominant RYR1-Related Myopathy
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 5 Neoplasm Metastasis
• Efficacy, Safety, and Tolerability of DYNE-101 in Participants with Myotonic Dystrophy Type 1 Pending
  2025-522957-20-00 5 Myotonic Dystrophy Type 1
• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5 Myelofibrosis
• SAVE trial Pending
  2025-523709-13-00 5 Acute ischemic stroke
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 5 2026-04-29 Advanced Platinum-resistant Epithelial Ovarian Cancer
• A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit … Recruiting
  2025-523204-68-00 4 2026-03-25 HER2-positive breast cancer
• A Global Phase 3 Open-Label Extension Study to Assess AOC 1001 in Patients with DM1 Recruiting
  2025-520766-22-00 5 2026-01-21 Myotonic Dystrophy Type 1
• A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting
  2023-507525-42-00 5 2025-12-23 Endometrial cancer
• A PHASE II, SINGLE-CENTER, RANDOMIZED DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF THE COMBINED THERAPY OF EH-301 AND N- … Recruiting
  2024-519857-13-00 9 2025-11-25 Amyotrophic Lateral Sclerosis (ALS)

Showing 1–24 of 200 trials